EGFR and non-small cell lung carcinoma: In order to overcome resistance, multiple agents have been studied to target MET or its ligand hepatocyte growth factor (HGF) and several MET inhibitors have been studied in association with EGFR TKIs or chemotherapeutic agents in NSCLC patients who developed resistance to TKIs [27].